Similar articles for PMID: 16970214

Year	Number of Results
1988	1
1991	1
1995	1
1996	1
1997	1
2000	1
2001	1
2002	4
2003	7
2004	12
2005	8
2006	17
2007	9
2008	9
2009	10
2010	8
2011	7
2012	14
2013	7
2014	6
2015	8
2016	5
2017	6
2018	9
2019	1
2020	5
2021	2
2022	16
2023	15
2024	0

1

Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial.

Pearson TA, Denke MA, McBride PE, Battisti WP, Gazzara RA, Brady WE, Palmisano J. Pearson TA, et al. Mayo Clin Proc. 2006 Sep;81(9):1177-85. doi: 10.4065/81.9.1177. Mayo Clin Proc. 2006. PMID: 16970214 Clinical Trial.

2

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.

Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Pearson T, et al. Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28. Am J Geriatr Pharmacother. 2005. PMID: 16503317 Clinical Trial.

3

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.

Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. Pearson TA, et al. Mayo Clin Proc. 2005 May;80(5):587-95. doi: 10.4065/80.5.587. Mayo Clin Proc. 2005. PMID: 15887425 Clinical Trial.

4

Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.

Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Denke M, et al. Diab Vasc Dis Res. 2006 Sep;3(2):93-102. doi: 10.3132/dvdr.2006.020. Diab Vasc Dis Res. 2006. PMID: 17058629 Free article. Clinical Trial.

5

A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.

Raal F, Schamroth C, Patel J, Becker P. Raal F, et al. Cardiovasc J Afr. 2007 Sep-Oct;18(5):325-9. Cardiovasc J Afr. 2007. PMID: 17985033 Free PMC article. Clinical Trial.

6

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Simons L, et al. Curr Med Res Opin. 2004 Sep;20(9):1437-45. doi: 10.1185/030079904x2321. Curr Med Res Opin. 2004. PMID: 15383192 Clinical Trial.

7

Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.

Chow D, Chen H, Glesby MJ, Busti A, Souza S, Andersen J, Kohrs S, Wu J, Koletar SL. Chow D, et al. AIDS. 2009 Oct 23;23(16):2133-41. doi: 10.1097/QAD.0b013e32833068e3. AIDS. 2009. PMID: 19770624 Free PMC article. Clinical Trial.

8

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL. Ballantyne CM, et al. Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29. Eur J Prev Cardiol. 2020. PMID: 31357887 Free PMC article. Clinical Trial.

9

Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial.

Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Yu CC, et al. BMC Res Notes. 2012 May 23;5:251. doi: 10.1186/1756-0500-5-251. BMC Res Notes. 2012. PMID: 22621316 Free PMC article. Clinical Trial.

10

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K. Foody JM, et al. Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15. Vasc Health Risk Manag. 2013. PMID: 24265554 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

180 results

Results by year